Evidence map›Paper›PMID 31641018›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2020

Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates.

Brian D Kangas, Ani S Zakarian, Kiran Vemuri, Shakiru O Alapafuja, Shan Jiang, Spyros P Nikas, Alexandros Makriyannis, Jack Bergman

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Brian D KangasDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.) bkangas@mclean.harvard.edu.
Ani S ZakarianDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
Kiran VemuriDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
Shakiru O AlapafujaDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
Shan JiangDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
Spyros P NikasDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
Alexandros MakriyannisDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
Jack BergmanDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
Harvard University · USNortheastern University · US

Funding

Project 3 - In vivo pharmacology of cannabinoid receptor probesP01DA009158 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI Alexandros Makriyannis · 1994 to 2026
$26.0M
Neural, Cognitive and Abuse-Related Consequences of Chronic THC Exposure during Adolescence in Nonhuman PrimatesR01DA047575 · NIDA · MCLEAN HOSPITAL · PI JACK BERGMAN, Brian D. Kangas · 2019 to 2026
$5.7M
A CB1 Antagonist for Treatment of Kidney DiseaseR44DK139888 · NIDDK · MAKSCIENTIFIC, LLC · PI ALAPAFUJA, SHAKIRU OLAJIRE · 2024 to 2024
$573k
Antidotes for Acute Cannabinoid IntoxicationR21DA045882 · NIDA · NORTHEASTERN UNIVERSITY · PI MAKRIYANNIS, ALEXANDROS · 2018 to 2019
$416k
Cannabinergic Receptor Antagonists for Nicotine AddictionR43DA036982 · NIDA · MAKSCIENTIFIC, LLC · PI ALAPAFUJA, SHAKIRU OLAJIRE · 2014 to 2014
$222k
NIDA NIH HHS P01 DA009158NIDA NIH HHS R01 DA047575NIDA NIH HHS R21 DA045882NIDA NIH HHS R43 DA036982NIDDK NIH HHS R44 DK139888
6 · The paper itself

Abstract

Despite a growing acceptance that withdrawal symptoms can emerge following discontinuation of cannabis products, especially in high-intake chronic users, there are no Food and Drug Administration (FDA)-approved treatment options. Drug development has been hampered by difficulties studying cannabis withdrawal in laboratory animals. One preclinical approach that has been effective in studying withdrawal from drugs in several pharmacological classes is antagonist drug discrimination. The present studies were designed to examine this paradigm in squirrel monkeys treated daily with the long-acting CB

Indexed as

Discrimination, PsychologicalDisease Models, AnimalAnimalsBenzopyransCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsDrug Evaluation, PreclinicalDrug SubstitutionMaleRimonabantSaimiriSubstance Withdrawal Syndrome3-(1-hexylcyclobut-1-yl)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo(b,d)pyran-1,9 diolBenzopyransCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsRimonabant

Identifiers

PMID31641018
PMCPMC6927407
OpenAlexW2981416247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.